↓ Skip to main content

Dove Medical Press

Article Metrics

Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report

Overview of attention for article published in Therapeutics and Clinical Risk Management, October 2014
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
28 Mendeley
Title
Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report
Published in
Therapeutics and Clinical Risk Management, October 2014
DOI 10.2147/tcrm.s70545
Pubmed ID
Authors

Petru Ifteni, Marius Alexandru Moga Moga, Victoria Burtea, Christoph U Correll

Abstract

Women with schizophrenia have a high risk for symptom exacerbation or relapse during pregnancy and thereafter. Relapses are more frequent when antipsychotics are discontinued. This paper describes the case of a 28-year old woman with schizophrenia who continued treatment with olanzapine during the first trimester. Olanzapine, a second-generation antipsychotic, was administered at a therapeutic dose from week 1 of gestation until week 13 when she reported the pregnancy to her psychiatrist. Despite the psychiatrist's recommendation to continue treatment, the patient stopped olanzapine at 20 weeks. She was hospitalized at week 36 for a schizophrenia relapse and was transferred to the obstetrics department where she gave birth by Cesarean section to a normal child. This case is important, illustrating the perils of unplanned pregnancy during antipsychotic treatment and abrupt discontinuation. Ultimately, clinical decisions should be made on a case-by-case basis, weighing the risks to the mother in terms of symptom exacerbation and relapse if antipsychotic treatment is discontinued, and the potential risk to the fetus regarding possible teratogenic effects of continued antipsychotic treatment.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 14%
Student > Doctoral Student 4 14%
Student > Bachelor 3 11%
Student > Master 3 11%
Lecturer 2 7%
Other 8 29%
Unknown 4 14%
Readers by discipline Count As %
Medicine and Dentistry 11 39%
Psychology 6 21%
Nursing and Health Professions 2 7%
Computer Science 1 4%
Neuroscience 1 4%
Other 0 0%
Unknown 7 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2014.
All research outputs
#9,993,258
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#764
of 922 outputs
Outputs of similar age
#156,379
of 232,345 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#5
of 5 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 232,345 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.